-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
The antibacterial, anti-inflammatory and antiviral properties of azithromycin suggest its therapeutic potential for COVID-19, and its efficacy for patients with mild to moderate COVID-19 is still unknown
.
A study in the journal Lancet Respir Med evaluated whether azithromycin can effectively reduce hospitalization or mortality in patients with mild to moderate COVID-19 who are receiving treatment in the outpatient clinic
The antibacterial, anti-inflammatory and antiviral properties of azithromycin suggest its therapeutic potential for COVID-19, and its efficacy for patients with mild to moderate COVID-19 is still unknown
The study was conducted in 19 hospitals in the UK, using a prospective, open, randomized advantage trial
.
Recruit adults over 18 years of age who have been clinically diagnosed , highly probable or confirmed COVID-19 infection , with symptoms less than 14 days, suitable for initial outpatient treatment
The study was conducted in 19 hospitals in the UK, using a prospective, open, randomized advantage trial
From June 3, 2020 to January 29, 2021, 298 patients were enrolled in the study
The average age of the patients was 45.
Studies have shown that in outpatients with mild to moderate COVID-19, the addition of azithromycin to standard treatment does not reduce the risk of hospitalization, respiratory failure or death
.
The results of the study do not support the use of azithromycin in patients with mild to moderate COVID-19
Studies have shown that in outpatients with mild to moderate COVID-19, the addition of azithromycin to standard treatment does not reduce the risk of hospitalization, respiratory failure or death
Original source:
Timothy SC Hinks, Lucy Cureton, Ruth Knight, et al, Azithromycin versus standard care in patients with mild-to-moderate COVID-19 (ATOMIC2): an open-label, randomised trial .
Timothy SC Hinks, Lucy Cureton, Ruth Knight, et al, Azithromycin versus standard care in patients with mild-to-moderate COVID-19 (ATOMIC2): an open-label, randomised trial .
Leave a message here
